Fasenra/benralizumab Cost, Side effects, Dosage, Uses for severe asthma

Fasenra/benralizumab Cost, Side effects, Dosage, Uses for severe asthma. US FDA granted approval of  Fasenra to AstraZeneca Pharmaceuticals.

US FDA approved new drug Fasenra that contains active pharmaceutical ingredient benralizumab which is monoclonal antibody for the treatment of  patients with severe asthma having  eosinophilic phenotype. US FDA approved this drug as add-on maintenance therapy in the treatment of severe
asthma. US FDA also instructed about this drug usage limitation means that it is not for treatment of other eosinophilic conditions or for relief of acute bronchospasm or status asthmaticus.

Asthma is a chronic disease that causes inflammation in the airways of the lungs. During an asthma attack, airways become narrow making it hard to breathe. Severe asthma attacks can lead to asthma-related hospitalizations because these attacks can be serious and even life-threatening.

According to the Centers for Disease Control and Prevention, as of 2013, more than 22 million people in the U.S. have asthma, and there are more than 400,000 asthma-related hospitalizations each year.

Benralizumab is a humanized afucosylated, monoclonal antibody (IgG1, kappa) that directly binds to the alpha subunit of the human interleukin-5 receptor (IL-5Rα) with a dissociation constant of 11 pM. The IL-5 receptor is expressed on the surface of eosinophils and basophils. In an in vitro setting, the absence of fucose in the Fc domain of benralizumab facilitates binding (45.5 nM) to FcɣRIII receptors on immune effectors cells, such as natural killer (NK) cells, leading to apoptosis of eosinophils and basophils through antibody-dependent cell-mediated cytotoxicity (ADCC).


Fasenrabenralizumab Cost, Side effects, Dosage, Uses for severe asthma


Fasenra/benralizumab Side effects


Following side effects were observed during clinical trials of this drug


  • Headache
  • Hypersensitivity
  • Anaphylaxis
  • Pharyngitis
  • Rashes
  • Urticaria
  • Angioedema
  • Skin irritability

Fasenra/benralizumab Uses/Prescribing Information


This drug is approved for the treatment of  patients with severe asthma having  eosinophilic phenotype. US FDA approved this drug as add-on maintenance therapy in the treatment of severe
asthma. US FDA also instructed about this drug usage limitation means that it is not for treatment of other eosinophilic conditions or for relief of acute bronchospasm or status asthmaticus.

Fasenra/benralizumab Dosage


This drug is formulated in a single-dose prefilled syringe with potency of 30 mg/mL solution. Recommended dose is 30 mg every 4 weeks for the first 3 doses, followed by once every 8 weeks thereafter via subcutaneous injection.

Fasenra/benralizumab Cost


Fasenra/benralizumab cost is difficult to evaluate at the moment as according to market survey this drug is currently not available at retail pharmacies because it is recently approved by FDA and is under manufacturing process. Once, it will be available at retail outlets we will let you know about the unit cost of drug and its dosage frequency.

Share this

Related Posts

Previous
Next Post »

Leave a reply